TEXT SIZE
About
The Journal
Aims and Scope
Abstracting and
indexing Services
Editorial Board
View Full-text
Current Issue
Past Issues
ALM Search
Search Recent 2 yrs
ALM on
ALM on
Top 10 cited article
For Contributors
Instructions to Authors
Standard abbreviation
e-Submission
Contact Us
Indexed in
KoreaMed
Medicus
PubMed
PubMed Central
JCR Science Edition
SCI Expanded

Annals of Laboratory Medicine
Condition   Expression Quick Search
When you enter More than two words, please use ‘and , or’ operation by means of putting ‘,(Comma Mark)’ between each word.
 
30(03) 255-259
A Case of Therapy-related ALL with MLL Gene Rearrangement Following Treatment of Breast Cancer
Jinhee Cho, M.D.1, Mina Hur, M.D1, Hee Won Moon, M.D.1, Yeo-Min Yun, M.D.1, Chang Hoon Lee, M.D.1, and Hong Ghi Lee M.D.2
Departments of Laboratory Medicine1 and Internal Medicine2, Konkuk University School of Medicine, Seoul, Korea
ALL with MLL gene rearrangement secondary to chemotherapy has been rarely reported. We report a case of therapy-related ALL (t-ALL) with MLL gene rearrangement in a patient who had undergone treatment for breast cancer. A 60-yr-old woman with breast cancer underwent breastconserving surgery followed by 6 cycles of adjuvant chemotherapy (cyclophosphamide, epirubicin, and fluorouracil) and radiation therapy (dose, 5,040 cGy to the left breast and a 1,000 cGy boost to the tumor bed). A follow-up examination performed 14 months after the chemotherapy revealed no evidence of breast malignancy. However, the patient’s complete blood cell count indicated acute leukemia: white blood cell count, 174.1×109/L with 88% blasts; Hb level, 12.5 g/dL; and platelet count, 103.0×109/L. Examination of the bone marrow aspirate smear revealed a high percentage of blasts (85.1% of all nucleated cells); the blasts showed a pro-B immunophenotype and were positive for CD19, CD79a, HLA-DR, CD34, and terminal deoxynucleotidyl transferase (TdT). Cytogenetic and FISH analyses revealed t(4;11)(q21;q23) and MLL gene rearrangement, respectively. The patient received induction chemotherapy with cyclophosphamide, vincristine, doxorubicin, and dexamethasone and achieved complete remission. Following consolidation chemotherapy, she underwent allogenic peripheral blood stem cell transplantation and has been clinically stable. To our knowledge, this is the first reported case of t-ALL with MLL gene rearrangement following treatment of breast cancer in Korea. (Korean J Lab Med 2010;30:255-9)
Korean J Lab Med 2010 Jun; 30(03) 255-259
Keyword : Therapy, ALL, Topoisomerase II inhibitor, MLL gene rearrangement